Related references
Note: Only part of the references are listed.Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials
James Bussel et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
A critical appraisal of the evidence for the role of splenectomy in adults and children with ITP
Francesco Rodeghiero
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Fostamatinib for persistent/chronic adult immune thrombocytopenia
Adrian Newland et al.
IMMUNOTHERAPY (2018)
Is ITP a thrombophilic disorder?
Francesco Rodeghiero
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study
Adrian Newland et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia
Ann Janssens et al.
ANNALS OF HEMATOLOGY (2016)
Population Pharmacokinetic and Pharmacodynamic Modeling of Lusutrombopag, a Newly Developed Oral Thrombopoietin Receptor Agonist, in Healthy Subjects
Takayuki Katsube et al.
CLINICAL PHARMACOKINETICS (2016)
Thromboembolism in adults with primary immune thrombocytopenia: a systematic literature review and meta-analysis
Indraraj Umesh Doobaree et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2016)
Romiplostim Treatment in Adults with Immune Thrombocytopenia of Varying Duration and Severity
Ann Janssens et al.
ACTA HAEMATOLOGICA (2015)
Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim
Douglas B. Cines et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2015)
A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia
James B. Bussel et al.
BLOOD (2014)
Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors
M. Ruggeri et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2014)
Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia
Soames Boyle et al.
BLOOD (2013)
Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy
David J. Kuter et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3.5 years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP)
Yukari Shirasugi et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2012)
Platelet Kinetics in Idiopathic Thrombocytopenic Purpura Patients Treated with Thrombopoietin Receptor Agonists
Oliver Meyer et al.
TRANSFUSION MEDICINE AND HEMOTHERAPY (2012)
The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia
Cindy Neunert et al.
BLOOD (2011)
Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial
Yukari Shirasugi et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2011)
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia
Francesco Zaja et al.
BLOOD (2010)
Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database
Ameet Sarpatwari et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia.
David J. Kuter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group
Francesco Rodeghiero et al.
BLOOD (2009)
A phase II, open-label, sequential-cohort, dose-escalation study of romiplostim in Japanese patients with chronic immune thrombocytopenic purpura
Yukari Shirasugi et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2009)
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura:: a double-blind randomised controlled trial
David J. Kuter et al.
LANCET (2008)
Idiopathic thrombocytopenic purpura: Current concepts in pathophysiology and management
Roberto Stasi et al.
THROMBOSIS AND HAEMOSTASIS (2008)
The pathogenesis of chronic immune thrombocytopenic purpura
Robert McMillan
SEMINARS IN HEMATOLOGY (2007)
An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura
Adrian Newland et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP
James B. Bussel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP
R McMillan et al.
BLOOD (2004)
T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura
B Olsson et al.
NATURE MEDICINE (2003)
Share Paper
